Dr. Saral Mehra earned his Medical Degree from Columbia University’s College of Physicians and Surgeons in New York City, and a Masters in Business Administration from Columbia Business School. He then completed a residency in Otolaryngology/Head and Neck Surgery at New York Presbyterian Hospital / Memorial Sloan Kettering Cancer Center. During residency Dr. Mehra was award the Department’s research award twice, the Department’s teaching award at his graduation, and the Distinguished House Staff award from New York Hospital.
Subsequently, he pursued advanced Fellowship training in Head and Neck and Thyroid Cancer at Beth Israel Medical Center with a special emphasis on Reconstructive Surgery including the use of free tissue transfer through state-of the art microvascular surgical techniques.
Currently, Dr. Mehra’s clinical practice focuses on treating patients with Head and Neck and Thyroid diseases, particularly cancer, including advanced reconstruction and rehabilitation. While trained in treating advanced and recurrent cancers, he also has special training in minimally invasive techniques such as salivary endoscopy, laser surgery, and robotic surgery. His primary research interests are in measuring and improving the quality of life in patients being treated for head and neck cancers, as well as leveraging his Business education to perform Health Services research with the goal of improving the quality of care delivered to such patients.
Dr. Mehra has presented original research at many National and International meetings, has already published nearly a dozen articles in peer-reviewed journals, and has a number of book chapters and research articles soon to be published.
- Medical Oncology
- Skin Neoplasms
- General Surgery
- Surgery, Plastic
- Craniofacial Abnormalities
Accepts new patients? Yes
Patient Type: Adult; Adolescent; Child; Geriatric
Referrals: From patients or physicians
Patient Care Organizations
Otolaryngology AB of Otolaryngology (2013)
|Larynx, Lip, Oral Cavity and Pharynx, Thyroid||Study of Pembrolizumab (MK-3475) for 1st Line Tx of Recurrent/Metastatic Squamous Cell Ca of H&N|
|Lip, Oral Cavity and Pharynx||Individualized treatment for nasopharyngeal cancer based on the patient's DNA|
|Larynx||RTOG 3501 (TRYHARD)|
|Larynx, Lip, Oral Cavity and Pharynx||RTOG 0920: Phase III Postoperative IMRT +/- Cetuximab, Locally-Advanced Head & Neck Cancer|